The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study

Aim: This study examined the real-world effectiveness and safety outcomes of vedolizumab in ulcerative colitis (UC) patients who had failed anti-tumor necrosis factor (anti-TNF) therapy in Korea. Methods: A retrospective chart review study was conducted in adults with moderate to severely active UC...

Full description

Bibliographic Details
Main Authors:	Byong Duk Ye, Jae Hee Cheon, Ki Hwan Song, Joo Sung Kim, Young-Ho Kim, Hyuk Yoon, Kang-Moon Lee, Sang-Bum Kang, Byung Ik Jang, Jae Jun Park, Tae Oh Kim, Dae-Wook Lee, Chee Yoong Foo, Jeong Eun Shin, Dong Il Park
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-07-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/17562848211024769

Similar Items

Patient considerations in the management of ulcerative colitis – role of vedolizumab
by: Kothari M, et al.
Published: (2015-08-01)

New and emerging treatments for ulcerative colitis: a focus on vedolizumab
by: Gledhill T, et al.
Published: (2013-05-01)

Is infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
by: Dae Bum Kim, et al.
Published: (2018-04-01)

The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis
by: Neal Shahidi, et al.
Published: (2016-05-01)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
by: Dart RJ, et al.
Published: (2017-03-01)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
by: Gilroy L, et al.
Published: (2014-05-01)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
by: Holger Schäffler, et al.
Published: (2017-12-01)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
by: Choon Jin Ooi, et al.
Published: (2021-01-01)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
by: Patrizio Scarozza, et al.
Published: (2020-02-01)

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
by: Wilson MR, et al.
Published: (2017-10-01)

Atypical Distribution of Inflammation in Newly Diagnosed Ulcerative Colitis is not Rare
by: Sang Hyoung Park, et al.
Published: (2014-01-01)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
by: Hiroyuki Okamoto, et al.
Published: (2021-01-01)

Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
by: Petkau JM, et al.
Published: (2016-03-01)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
by: Friederike Fuchs, et al.
Published: (2017-07-01)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
by: Fabiana Zingone, et al.
Published: (2020-07-01)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
by: Carter, J.A, et al.
Published: (2021)

Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis
by: Daisuke Saito, et al.
Published: (2021-09-01)

A case of ulcerative colitis presenting with cerebral venous thrombosis
by: Junghwan Lee, et al.
Published: (2018-04-01)

Multiple Pyoderma Gangrenosum in Ulcerative Colitis
by: Sung Bum Kim, et al.
Published: (2018-09-01)

Immunoglobulin A vasculitis in an adult patient receiving vedolizumab therapy for ulcerative colitis: A case report
by: http://www.mdpub.net/index.php?fulltxt=68728&fulltxtj=172&fulltxtp=172-1570485169.pdf
Published: (2019-11-01)

Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn’s disease
by: Matteo Ruggeri, et al.
Published: (2017-04-01)

Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study)
by: Halina Cichoż-Lach, et al.
Published: (2021-08-01)

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis
by: Sun-Ho Lee, et al.
Published: (2017-10-01)

Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis
by: Myoungrin Park, et al.
Published: (2019-04-01)

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
by: Shin Ju Oh, et al.
Published: (2021-07-01)

Cytomegalovirus Gastric Ulcer Complicated with Pyloric Obstruction in a Patient with Ulcerative Colitis
by: Sung Hwan Kang, et al.
Published: (2017-06-01)

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis
by: Jun Miyoshi, et al.
Published: (2021-08-01)

Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
by: Satoshi Motoya, et al.
Published: (2019-01-01)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
by: Pawel Petryszyn, et al.
Published: (2020-08-01)

Coexistence of Solitary Rectal Ulcer Syndrome and Ulcerative Colitis: A Case Report and Literature Review
by: Hyun Bum Park, et al.
Published: (2014-01-01)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
by: Hyun Il Seo, et al.
Published: (2014-07-01)

Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis
by: Seok-Hwan Kim, et al.
Published: (2017-07-01)

Chronic recurrent multifocal osteomyelitis of the left femur associated with ulcerative colitis: a case report
by: Min Cheol Kim, et al.
Published: (2021-09-01)

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
by: Satoshi Motoya, et al.
Published: (2019-01-01)

Peritonsillar Involvement in Pyoderma Gangrenosum associated with Ulcerative Colitis
by: Yu Mi Byeon, et al.
Published: (2014-04-01)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
by: Ting Zhou, et al.
Published: (2021-08-01)

Can narrow-band imaging of Peyer's patches predict the recurrence of ulcerative colitis?
by: Yoon Jae Kim
Published: (2016-10-01)

The Beneficial Effect of Vanillic Acid on Ulcerative Colitis
by: Seung-Heon Hong, et al.
Published: (2010-10-01)

Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study
by: Kwangwoo Nam, et al.
Published: (2021-01-01)